Published in Nat Med on March 14, 2010
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 2.34
Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol (2012) 2.25
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release (2012) 2.12
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov (2013) 1.93
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia (2013) 1.76
Bioluminescence imaging: progress and applications. Trends Biotechnol (2011) 1.59
Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2014) 1.57
Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol (2013) 1.57
The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med (2015) 1.50
The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol (2012) 1.46
A causal relation between bioluminescence and oxygen to quantify the cell niche. PLoS One (2014) 1.44
ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene (2011) 1.42
Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets (2011) 1.38
In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals. Sensors (Basel) (2010) 1.33
Expedient synthesis of electronically modified luciferins for bioluminescence imaging. J Am Chem Soc (2012) 1.30
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood (2012) 1.23
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol (2012) 1.12
Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2011) 1.10
Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells. PLoS One (2010) 1.08
Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun (2015) 1.08
Proteome-scale Binary Interactomics in Human Cells. Mol Cell Proteomics (2016) 1.07
Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res (2011) 1.06
The tumor microenvironment controls drug sensitivity. Nat Med (2012) 1.05
Small-molecule inhibitors of the Myc oncoprotein. Biochim Biophys Acta (2014) 0.98
Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation. PLoS One (2011) 0.95
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther (2012) 0.94
Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Mol Cancer Res (2015) 0.93
Future agents and treatment directions in multiple myeloma. Expert Rev Hematol (2013) 0.92
Cell-selective labeling using amino acid precursors for proteomic studies of multicellular environments. Nat Methods (2013) 0.92
Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS One (2013) 0.91
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood (2012) 0.91
Navigating the bone marrow niche: translational insights and cancer-driven dysfunction. Nat Rev Rheumatol (2015) 0.90
Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer. Mol Cancer Ther (2015) 0.90
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol (2013) 0.89
Fibroblasts--a key host cell type in tumor initiation, progression, and metastasis. Ups J Med Sci (2012) 0.88
Personalized therapies in the cancer "omics" era. Mol Cancer (2010) 0.88
Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ. J Breast Cancer (2012) 0.88
The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene (2015) 0.87
Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells. PLoS One (2013) 0.86
Enzymatic transformation of phosphate decorated magnetic nanoparticles for selectively sorting and inhibiting cancer cells. Bioconjug Chem (2014) 0.86
Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype. Mol Cancer Ther (2011) 0.86
Inhibition of tumor cells interacting with stromal cells by xanthones isolated from a Costa Rican Penicillium sp. J Nat Prod (2012) 0.86
Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay. PLoS One (2014) 0.85
Distinctive responsiveness to stromal signaling accompanies histologic grade programming of cancer cells. PLoS One (2011) 0.85
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol (2011) 0.85
The anti-cancer agent SU4312 unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS. Br J Pharmacol (2013) 0.85
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms. Mol Oncol (2013) 0.84
Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support. Oncotarget (2014) 0.84
Directed molecular evolution reveals Gaussia luciferase variants with enhanced light output stability. Anal Chem (2013) 0.84
Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. PLoS One (2014) 0.84
Tumor talk: understanding the conversation between the tumor and its microenvironment. Cancer Cell Microenviron (2015) 0.84
Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. J Virol (2012) 0.84
Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone (2015) 0.83
Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures. Med Res Rev (2015) 0.83
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget (2014) 0.83
Functional multiplex reporter assay using tagged Gaussia luciferase. Sci Rep (2013) 0.83
Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma. Oncogene (2015) 0.83
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica (2016) 0.82
Microenvironment-mediated resistance to anticancer therapies. Cell Res (2012) 0.82
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol (2012) 0.82
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. J Clin Invest (2015) 0.82
The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. Oncogene (2013) 0.82
Game theory in the death galaxy: interaction of cancer and stromal cells in tumour microenvironment. Interface Focus (2014) 0.82
Synergistic antitumor activity of reversine combined with aspirin in cervical carcinoma in vitro and in vivo. Cytotechnology (2013) 0.82
Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients. EPMA J (2010) 0.81
Resolving cancer-stroma interfacial signalling and interventions with micropatterned tumour-stromal assays. Nat Commun (2014) 0.81
Proteomic profiling of the tumor microenvironment: recent insights and the search for biomarkers. Genome Med (2014) 0.81
Generation and functional assessment of 3D multicellular spheroids in droplet based microfluidics platform. Lab Chip (2016) 0.81
Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics. Mol Cancer Ther (2014) 0.80
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells. J Vis Exp (2015) 0.80
Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF. Oncotarget (2015) 0.79
A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses. Oncogene (2015) 0.79
A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma. J Transl Med (2014) 0.79
Targeting focal adhesion turnover in invasive breast cancer cells by the purine derivative reversine. Br J Cancer (2013) 0.79
Modeling Selective Elimination of Quiescent Cancer Cells from Bone Marrow. Neoplasia (2015) 0.79
Progress and Paradigms in Multiple Myeloma. Clin Cancer Res (2016) 0.78
High-throughput approaches to discover novel immunomodulatory agents for cancer. Oncoimmunology (2012) 0.78
Microcavity substrates casted from self-assembled microsphere monolayers for spheroid cell culture. Biomed Microdevices (2014) 0.78
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers (Basel) (2017) 0.77
A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia. J Biomol Screen (2013) 0.77
Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. Cell Rep (2015) 0.77
Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models. Cancers (Basel) (2013) 0.77
Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies. Indian J Surg Oncol (2016) 0.76
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget (2016) 0.76
Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy. J Cancer Res Clin Oncol (2014) 0.76
Ectoenzyme switches the surface of magnetic nanoparticles for selective binding of cancer cells. J Colloid Interface Sci (2014) 0.76
Drug screening: shedding light on tumour-stroma interactions. Nat Rev Drug Discov (2010) 0.75
Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. BMC Cancer (2015) 0.75
3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response. BMC Cancer (2016) 0.75
High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells. J Clin Invest (2016) 0.75
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res (2016) 0.75
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest (2016) 0.75
Overview of cancer vaccines: considerations for development. Hum Vaccin Immunother (2012) 0.75
Reversine Induced Multinucleated Cells, Cell Apoptosis and Autophagy in Human Non-Small Cell Lung Cancer Cells. PLoS One (2016) 0.75
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol (2003) 11.17
Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 9.68
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res (2001) 6.93
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature (2003) 6.78
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol (2003) 4.49
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Gene expression in human embryonic stem cell lines: unique molecular signature. Blood (2003) 3.73
Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev (2006) 3.72
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene (2001) 3.28
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature (2007) 3.21
Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer (2004) 3.19
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A (2000) 2.81
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood (2003) 2.41
Focus on multiple myeloma. Cancer Cell (2004) 2.10
Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med (1994) 2.05
Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood (2003) 1.92
Novel genes regulated by Sonic Hedgehog in pluripotent mesenchymal cells. Oncogene (2002) 1.51
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res (2003) 1.51
Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor. Ann N Y Acad Sci (2005) 1.44
Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res (2002) 1.22
The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am (1999) 1.20
Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res (2003) 1.18
The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol (1998) 1.11
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev (2005) 12.15
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 7.63
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
The roles of FLT3 in hematopoiesis and leukemia. Blood (2002) 6.14
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 4.82
Multiple myeloma. Lancet (2009) 4.60
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol (2003) 4.43
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer (2007) 3.36
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood (2008) 3.30
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A (2002) 3.28
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science (2003) 3.21
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12
HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood (2008) 3.12